Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.

Caroline W EspinolaYuelee KhooRoohie ParmarIlya DemchenkoBenicio Noronha FreyRoumen V MilevArun V RavindranSagar V ParikhKeith HoSusan RotzingerWendy LouRaymond W LamSidney H KennedyVenkat Bhatnull null

Published in: Brain and behavior (2022)

Patients on escitalopram and aripiprazole adjunctive therapy may experience and have trouble with CNS side effects. Pretreatment anxious depression may predispose escitalopram recipients with MDD to developing side effects, especially those related to anxiety.

Keyphrases

major depressive disorder
sleep quality
end stage renal disease
depressive symptoms
newly diagnosed
ejection fraction
chronic kidney disease
bipolar disorder
stem cells
mesenchymal stem cells
patient reported outcomes
bone marrow
smoking cessation